Long‐term safety and efficacy of glucagon‐like peptide‐1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study - Huang, Yu‐Nan; Liao, Wen‐Ling; Huang, Jing‐Yang; Lin, Yu‐Jung; Yang, Shun‐Fa; Huang, Chieh‐Chen; Wang, Chung‐Hsing; Su, Pen‐Hua (Diabetes, obesity & metabolism, 2024)
Keywords: Adult; adverse effects; Adverse events; Aged; Agonists; Allergies; Arrhythmia; cardiovascular disease; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Cohort analysis; Cohort Studies; Comorbidity; Congestive heart failure; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Female; GLP-1 receptor agonists; Glucagon; Glucagon-Like Peptide-1 Receptor Agonists; Heart diseases; Humans; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - therapeutic use; Ischemia; Male; Middle Aged; Obesity; Obesity - complications; Obesity - drug therapy; obesity management; Peptides; Propensity Score; Renal function; Retrospective Studies; Thyroid; thyroid dysfunction; Thyroid gland; Treatment Outcome; glucagon‐like peptide‐1 receptor agonists; adverse effects; cardiovascular disease; obesity management; thyroid dysfunction